2024
DOI: 10.3390/biomedicines12040826
|View full text |Cite
|
Sign up to set email alerts
|

NAFLD in the 21st Century: Current Knowledge Regarding Its Pathogenesis, Diagnosis and Therapeutics

Dimitris Kounatidis,
Natalia G. Vallianou,
Eleni Geladari
et al.

Abstract: Non-alcoholic fatty liver disease (NAFLD) is a major public health issue worldwide. It is the most common liver disease in Western countries, andits global prevalence is estimated to be up to 35%. However, its diagnosis may be elusive, because liver biopsy is relatively rarely performed and usually only in advanced stages of the disease. Therefore, several non-invasive scores may be applied to more easily diagnose and monitor NAFLD. In this review, we discuss the various biomarkers and imaging scores that coul… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(2 citation statements)
references
References 117 publications
0
2
0
Order By: Relevance
“…Due to the short half-life of human FGF-21, the development of FGF-21 analogs requires structural modifications to increase stability and avoid rapid elimination from the body [46]. An FGF-21 analog, pegozafermin (BIO89-100), was developed as subcutaneous injection for the therapy of MASH as well as severe hypertriglyceridemia [47]. Being pegylated, pegozafermin has a prolonged half-life compared to FGF-21, so it only needs to be administered once every 14 days [45].…”
Section: Fibroblast Growth Factor 21 (Fgf-21) Agonistsmentioning
confidence: 99%
See 1 more Smart Citation
“…Due to the short half-life of human FGF-21, the development of FGF-21 analogs requires structural modifications to increase stability and avoid rapid elimination from the body [46]. An FGF-21 analog, pegozafermin (BIO89-100), was developed as subcutaneous injection for the therapy of MASH as well as severe hypertriglyceridemia [47]. Being pegylated, pegozafermin has a prolonged half-life compared to FGF-21, so it only needs to be administered once every 14 days [45].…”
Section: Fibroblast Growth Factor 21 (Fgf-21) Agonistsmentioning
confidence: 99%
“…Based on these encouraging results, pegozafermin entered phase 3 clinical trials (NCT06318169) in March 2024 to evaluate the safety and efficacy of pegozafermin in patients with MASH and fibrosis. A total of 1050 patients will be enrolled in the study, which is expected to be completed in 2029 [47]. Efruxifermin, which exerts an agonistic effect on FGF-21, is another promising drug from this group.…”
Section: Fibroblast Growth Factor 21 (Fgf-21) Agonistsmentioning
confidence: 99%